Improving stone clearance after extracorporeal shock wave lithotripsy in urolithiasis patients by a special terpene combination (Rowatinex®): Results of a placebo-controlled, randomized trial

European Urology, Supplements

Volumn 9, Issue 12, 2010, Pages 819-825

  Romics, Imre ^a   Siller, György ^b   Kohnen, Ralf ^c   Mavrogenis, Stelios ^a   Varga, József ^d   Holman, Endre ^e  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Karolyi Hospital   (Hungary)

^c RPS   (United Kingdom)

^d Uzsoki Utcai Hospital   (Hungary)

^e Kiskunhalasi Semmelweis Kórház ^*  (Hungary)

Author keywords

Extracorporeal shock wave lithotripsy; Kidney stones; Rowatinex ; Terpenes; Urolithiasis

Indexed keywords

ANTIUROLITHIASIS AGENT; OLIVE OIL; PLACEBO; ROWATINEX; TERPENE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; EXTRACORPOREAL LITHOTRIPSY; FEMALE; FEVER; FOLLOW UP; HEMATURIA; HUMAN; INTRAVENOUS PYELOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; URETER STONE; UROLITHIASIS; VERTIGO; VOMITING; X RAY;

EID: 78650729941     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2010.11.007     Document Type: Article

References (29)

1. Healy K.A., Ogan K. Nonsurgical management of urolithiasis: an overview of expulsive therapy. J Endourol 2005, 19:759-767.
2. Park S. Medical management of urinary stone disease. Expert Opin Pharmacother 2007, 8:1117-1125.
3. Pietrow P.K., Karellas M.E. Medical management of common urinary calculi. Am Fam Physician 2006, 74:86-94.
4. Dawson C., Whitfield H.N. The long-term results of treatment of urinary stones. Br J Urol 1994, 74:397-404.
5. Kosar A., Sarica K., Aydos K., Kupeli S., Turkolmez K., Gogus O. Comparative study of long-term stone recurrence after extracorporeal shock wave lithotripsy and open stone surgery for kidney stones. Int J Urol 1999, 6:125-129.
6. Madaan S., Joyce A.D. Limitations of extracorporeal shock wave lithotripsy. Curr Opin Urol 2007, 17:109-113.
7. Galvin D.J., Pearle M.S. The contemporary management of renal and ureteric calculi. BJU Int 2006, 98:1283-1288.
8. Tan Y.H., Wong M. How significant are clinically insignificant residual fragments following lithotripsy?. Curr Opin Urol 2005, 15:127-131.
9. Tiselius HG, Alken P, Buck C, et al. Guidelines on Urolithiasis. European Association of Urology Web site. http://www.uroweb.org/fileadmin/user_upload/Guidelines/Urolithiasis.pdf.
10. Kim F.J., Rice K.R. Prediction of shockwave failure in patients with urinary tract stones. Curr Opin Urol 2006, 16:88-92.
11. El-Nahas A.R., El-Assmy A.M., Madbouly K., Sheir K.Z. Predictors of clinical significance of residual fragments after extracorporeal shockwave lithotripsy for renal stones. J Endourol 2006, 20:870-874.
12. Khaitan A., Gupta N.P., Hemal A.K., Dogra P.N., Seth A., Aron M. Post-ESWL, clinically insignificant residual stones: reality or myth?. Urology 2002, 59:20-24.
13. Siller G., Kottász S., Pálfi Z. ROWATINEX kapszula hatékonyságának vizsgálata ESWL-kezelés után keletkezett kofragmentumokra. Magyar Urológia 1998, 10:139-146.
14. Engelstein D., Kahan E., Servadio C. ROWATINEX for the treatment of ureterolithiasis. J Urol (Paris) 1992, 98:98-100.
15. Mukamel E., Engelstein D., Simon D., Servadio C. The value of ROWATINEX in the treatment of ureterolithiasis. J Urol (Paris) 1987, 93:31-33.
16. Asai J., Tsay Y.-C., Miyake K., Makino M. Treatment of urolithiasis with terpene preparation, ROWATINEX 1959, Department of Urology, Nagoya University, Nagoya, Japan.
17. Dufour A., Andre P. A report on the experiments carried out with ROWATINEX 1961, Hospital of Paris, Paris, France.
18. Geinitz W. The prevention of urinary calculi by ROWATINEX in animal experiments. Munch Med Wochenschr 1956, 98:895-897.
19. Hasegawa M., Toda T., Hara N., Doi S. Effect of the terpene combination in experimental calcium oxalate nephrolithiasis. Nishi Nihon Hinyo 1982, 44:213-220.
20. Hasegawa M., Toda T., Kitada H., et al. Effect of the terpene drug ROWATIN on experimental urolithiasis. Pharmacol Ther 1979, 7:3865-3875.
21. Caramia G., Di Gregorio L., Tarantino M.L., Galuffo A., Iacolino R., Caramia M. Uric acid, phosphate and oxalate stones: treatment and prophylaxis. Urol Int 2004, 72(Suppl 1):24-28.
22. Tanaka S., Handa T., Fukuhara M., Hara N., Doi S., Goto M. Effects of some the terpene combination on the activity product of calcium oxalate urolithiasis in rats. Iyakuhin Kenkyu 1982, 13:340.
23. Cipriani P., Mancini C. Microbiological activity of a terpene product used in the treatment of urinary diseases. Gazzetta Internazionale di Medicina e Chirurgia 1972, 77.
24. Huntington Research Center. Report on the bactericidal activity of ROWATINEX. 1961.
25. Kikuth W. Bacteriological study of the basic substances of ROWACHOL and ROWATINEX. 1955.
26. Horvath N. The use and effect of the terpene combination in nephrolithiasis. Arztliche Praxis 1963, 15:917-918.
27. Santos F.A., Rao V.S. Antiinflammatory and antinociceptive effects of 1,8-cineole a terpenoid oxide present in many plant essential oils. Phytother Res 2000, 14:240-244.
28. Santos F.A., Silva R.M., Campos A.R., De Araujo R.P., Lima Junior R.C., Rao V.S. 1,8-cineole (eucalyptol), a monoterpene oxide attenuates the colonic damage in rats on acute TNBS-colitis. Food Chem Toxicol 2004, 42:579-584.
29. Seitz C., Liatsikos E., Porpiglia F., Tiselius H.-G., Zwergel U. Medical therapy to facilitate the passage of stones: what is the evidence?. Eur Urol 2009, 56:455-471.